Penn Medicine and Parker Institute renew alliance to continue advancing groundbreaking cancer immunotherapy research
Penn Medicine and the Parker Institute for Cancer Immunotherapy (PICI) have renewed their collaboration to advance cancer immunotherapy research at Penn Medicine’s Abramson Cancer Center (ACC).
Penn spinout Verismo Therapeutics Makes Agreement to Fund University Research of KIR-CAR platform of Car-T to Target Solid Tumors
Learn about Penn spinout Verismo Therapeutics' agreement to fund four years of university research of KIR-CAR platform of Car-T to target solid tumors.
Gnubiotics and Penn Explore CAR-T Therapy
This collaboration will take place through company-sponsored pre-clinical research studies in the laboratory of Avery Posey, PhD, an assistant professor at the Perelman School of Medicine.
Five Years of Data Show Long-term Promise for Penn and Novartis’ Car-T Pioneer Kymriah
Five years after Penn and Novartis made history with the FDA approval of Kymriah, a recent study shows the long-term impact of the medication on patient remission rates.
The Center for Breakthrough Medicines and Penn partner in the manufacturing of gene therapies
Penn’s Innovation in Process Science combines with CBM manufacturing capability to develop large-scale gene therapy manufacturing capacity, testing, and analytics
Penn inventors named Heroes of the Year by Time Magazine
Drs. Katalin Kariko and Drew Weissman, inventors of the foundational RNA research that led to the COVID-19 vaccines, are two of researchers named by Time Magazine as their Heroes of the Year 2021.
Passage Bio further expands Gene Therapy research partnership with Penn
Passage Bio has exercised two additional options for potential new drug candidates under its research collaboration with Penn's gene therapy program.
Celebration of Innovation 2021 Recap and Recording
The event honors the patent recipients from the previous fiscal year, as well as, those partners, inventors, and startups that made exceptional achievements.
Jean Bennett, M.D., Ph.D., joins REGENXBIO Board of Directors
She will serve as a member of REGENXBIO's Nominating and Corporate Governance Committee.
iECURE emerges with $50M to search for ‘holy grail’ and ‘untapped frontier’ of gene editing
The biotech will use the funds for a slate of gene insertion programs for liver disorders out of the lab of gene therapy pioneer Jim Wilson, M.D., Ph.D. at Penn.